TrialLeukemia research2015

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.

Mark C Lanasa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.